© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
Our deeply rooted compassion drives us to go beyond delivering life-changing therapies. We strive to positively impact the many aspects of rare patients’ lives.
Chris Cline, CFA, is a senior vice president and member of the executive team at Travere Therapeutics. He is responsible for leading the company’s investor and capital markets engagement, as well as the corporate communications strategy. Since joining Travere Therapeutics in 2014, Mr. Cline has helped strengthen the company’s financial foundation through successful equity and debt offerings, and led the development of a dynamic corporate communications platform. Prior to Travere Therapeutics, Mr. Cline was a member of the global investor relations group at Elan Corporation, plc., an Ireland-based biotechnology company focused on neuroscience that was acquired by Perrigo Company. Before his time at Elan, Mr. Cline was a financial analyst in the corporate finance group at Phase Forward, a healthcare technology company with a focus on supporting growth through mergers and acquisitions. Mr. Cline is a chartered financial analyst and an active member of the National Investor Relations Institute. He received his BSBA in finance from the Williams College of Business at Xavier University.